Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Context Therapeutics Inc
(NQ:
CNTX
)
2.500
-0.030 (-1.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Context Therapeutics Inc
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
August 07, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
August 01, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
July 10, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
May 08, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
May 02, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces $100 Million Private Placement
May 02, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
April 01, 2024
Important Regulatory Milestone Supports Next Phase of CTIM-76 Development
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
March 21, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
November 09, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
October 31, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
August 10, 2023
Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr takes Proactive's Stephen Gunnion through progress with the company's lead program, CTIM-76.
Via
TheNewswire.com
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
August 09, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics to Participate in Two August 2023 Investor Conferences
August 01, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN
June 05, 2023
Via
AB Newswire
Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
May 10, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference
April 18, 2023
Via
ACCESSWIRE
Context Therapeutics to Participate in Two April 2023 Investor Conferences
April 03, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
March 22, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 15, 2023
Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
February 06, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
January 31, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
January 09, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
January 04, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
December 08, 2022
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
November 29, 2022
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
November 21, 2022
Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
November 09, 2022
From
Context Therapeutics Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.